Brandywine Global Investment Management LLC Lowers Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Brandywine Global Investment Management LLC decreased its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 59.7% during the fourth quarter, HoldingsChannel reports. The firm owned 100,971 shares of the specialty pharmaceutical company’s stock after selling 149,402 shares during the period. Brandywine Global Investment Management LLC’s holdings in Collegium Pharmaceutical were worth $2,893,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. New Age Alpha Advisors LLC purchased a new position in Collegium Pharmaceutical during the fourth quarter valued at approximately $40,000. TD Private Client Wealth LLC lifted its stake in shares of Collegium Pharmaceutical by 39.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after purchasing an additional 483 shares during the last quarter. KBC Group NV boosted its position in Collegium Pharmaceutical by 72.5% during the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock valued at $67,000 after purchasing an additional 982 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in Collegium Pharmaceutical by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after purchasing an additional 316 shares during the last quarter. Finally, Virtus Fund Advisers LLC bought a new position in Collegium Pharmaceutical in the third quarter worth about $72,000.

Insider Buying and Selling at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 977 shares of the company’s stock in a transaction on Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $29,310.00. Following the sale, the chief financial officer now directly owns 164,269 shares of the company’s stock, valued at approximately $4,928,070. This represents a 0.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of Collegium Pharmaceutical stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total value of $1,123,200.00. Following the transaction, the executive vice president now owns 154,204 shares of the company’s stock, valued at $4,330,048.32. The trade was a 20.60 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 109,193 shares of company stock worth $3,243,594. Company insiders own 3.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on COLL shares. Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a report on Friday, January 10th. Piper Sandler cut their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a report on Tuesday, February 4th. Finally, HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Monday, March 24th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $43.60.

Collegium Pharmaceutical Trading Up 2.1 %

NASDAQ COLL opened at $30.00 on Thursday. The stock has a market cap of $944.58 million, a P/E ratio of 12.93 and a beta of 0.99. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical, Inc. has a 12-month low of $27.28 and a 12-month high of $42.29. The company has a fifty day simple moving average of $30.16 and a two-hundred day simple moving average of $32.28.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The business had revenue of $181.95 million for the quarter, compared to the consensus estimate of $179.68 million. On average, analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.